Your browser doesn't support javascript.
loading
Improving outcome measures in late onset Pompe disease: Modified Rasch-Built Pompe-Specific Activity scale.
van Kooten, Harmke A; Horton, Mike C; Wenninger, Stephan; Babacic, Haris; Schoser, Benedikt; Lefeuvre, Claire; Taouagh, Najib; Laforêt, Pascal; Segovia, Sonia; Díaz-Manera, Jordi; Claeys, Kristl G; Mongini, Tiziana; Musumeci, Olimpia; Toscano, Antonio; Hundsberger, Thomas; Brusse, Esther; van Doorn, Pieter A; van der Ploeg, Ans T; van der Beek, Nadine A M E.
Affiliation
  • van Kooten HA; Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Horton MC; Psychometric Laboratory for Health Sciences, University of Leeds, Leeds, UK.
  • Wenninger S; Department of Neurology, Friedrich Baur Institute, Ludwig Maximilian University, Munich, Germany.
  • Babacic H; Department of Neurology, Friedrich Baur Institute, Ludwig Maximilian University, Munich, Germany.
  • Schoser B; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
  • Lefeuvre C; Department of Neurology, Friedrich Baur Institute, Ludwig Maximilian University, Munich, Germany.
  • Taouagh N; Département de Neurologie, Hôpital Raymond Poincaré, Paris, France.
  • Laforêt P; Département de Neurologie, Hôpital Raymond Poincaré, Paris, France.
  • Segovia S; Département de Neurologie, Hôpital Raymond Poincaré, Paris, France.
  • Díaz-Manera J; John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, UK.
  • Claeys KG; John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, UK.
  • Mongini T; Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
  • Musumeci O; Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Toscano A; Department of Neurosciences Rita Levi Montalcini, Università degli Studi di Torino, Turin, Italy.
  • Hundsberger T; Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
  • Brusse E; Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
  • van Doorn PA; Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • van der Ploeg AT; Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • van der Beek NAME; Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Eur J Neurol ; : e16397, 2024 Aug 28.
Article in En | MEDLINE | ID: mdl-39205420
ABSTRACT
BACKGROUND AND

PURPOSE:

The Rasch-Built Pompe-Specific Activity (R-PAct) scale is a patient-reported outcome measure specifically designed to quantify the effects of Pompe disease on daily life activities, developed for use in Dutch- and English-speaking countries. This study aimed to validate the R-PAct for use in other countries.

METHODS:

Four other language versions (German, French, Italian, and Spanish) of the R-PAct were created and distributed among Pompe patients (≥16 years old) in Germany, France, Spain, Italy, and Switzerland and pooled with data of newly diagnosed patients from Australia, Belgium, Canada, the Netherlands, New Zealand, the USA, and the UK and the original validation cohort (n = 186). The psychometric properties of the scale were assessed by exploratory factor analysis and Rasch analysis.

RESULTS:

Data for 520 patients were eligible for analysis. Exploratory factor analysis suggested that the items separated into two domains Activities of Daily Living and Mobility. Both domains independently displayed adequate Rasch model measurement properties, following the removal of one item ("Are you able to practice a sport?") from the Mobility domain, and can be added together to form a "higher order" factor as well. Differential item functioning (DIF)-by-language assessment indicated DIF for several items; however, the impact of accounting for DIF was negligible. We recalibrated the nomogram (raw score interval-level transformation) for the updated 17-item R-PAct scale. The minimal detectable change value was 13.85 for the overall R-PAct.

CONCLUSIONS:

After removing one item, the modified-R-PAct scale is a valid disease-specific patient-reported outcome measure for patients with Pompe disease across multiple countries.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur J Neurol Journal subject: NEUROLOGIA Year: 2024 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur J Neurol Journal subject: NEUROLOGIA Year: 2024 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom